Slaughter and May, Hong Kong, advised Citigroup Global Markets Limited and J.P. Morgan Securities (Asia Pacific) Limited, as placing agents, in relation to the placing of 15,000,000 new ordinary shares in Ascentage Pharma Group International (Ascentage). The net proceeds of the placing is approximately HK$689.5 million and will be used for (i) registration, trial production and marketing of the company’s core product; (ii) clinical development of other pipeline products, and (iii) general corporate use.
Ascentage is a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. It was listed on the Main Board of the Stock Exchange of Hong Kong on 28 October 2019.
Hong Kong